The retinal vein occlusion treatment market is evolving and is anticipated to experience moderate growth over the forecast period 2025 USD 2,579.4 Million to 2035 USD 4,323.1 Million, with a CAGR of 5.3%. Some of the major trends driving the growth of the market include increasing incidence and prevalence of ocular vascular diseases, increasing geriatric population, and rising adoption of intravitreal therapies.
Retinal vein occlusion (RVO, specifically CRVO and BRVO) continues to be one of the leading causes of vision impairment worldwide and hence, management is often chronic and can involve anti-VEGF injections, corticosteroids, and laser photocoagulation.
Segments are expected to be growing the definite detailed market segments, as per the progressive technological progresses in ocular drug delivery systems, the growth is expected to grow this market in the upcoming years, unavailability of inclination and awareness towards early diagnosis for eyes care is restraining the market. The growing collaborations of biopharmaceutical companies and ophthalmic facilities are driving innovative therapeutics for retinal vascular disorders.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 2,579.4 Million |
| Market Value (2035F) | USD 4,323.1 Million |
| CAGR (2025 to 2035) | 5.3% |
Explore FMI!
Book a free demo
The North America represents the largest share of the market for retinal vein occlusion treatment, due to significant prevalence of the condition, advances in technologies in health care infrastructure and availability of advanced intravitreal treatment options. Despite these limited indications, the USA ranibizumab and aflibercept market is characterized by a growing uptake, driven by good reimbursement policies and an aging population.
This new market momentum is also likely to fuel emerging clinical trials of long-acting delivery systems as well as gene therapy based approaches. A similar trend has been observed in Canada, though on a smaller scale, with an increasing number of ophthalmic consultations and uptake of minimally invasive treatment modalities.
The European Region has shown considerable demand for RVO treatments, particularly in Germany, France, Italy, and the UK, where the aging population and chronic diseases are increasing year on year. The European supports for biosimilars and cost-effective therapies are supporting even broader adoption in retinal applications.
Also, ophthalmology R&D, investment and leading pharma companies in the region encourage innovation and products development. Even in Western Europe, hospitals and eye clinics are onboard to identify retinal vascular complications at an earlier stage of development, by integrating teleophthalmology platforms.
The region that potentially has the strongest growth for retinal vein occlusion treatment is Asia-Pacific, driven by rising diabetes prevalence, aging demographics and increasing awareness of vision-related disorders. The increasing demand for anti-VEGF and corticosteroid therapies in countries like China, Japan, South Korea, and India Although accessibility in the form of ophthalmic clinics and diagnostic facilities is a challenge in themselves, urban centers witness a significant proliferation of such facilities. Government initiatives and public-private partnerships leading to early screening programs will likely increase diagnosis and treatment rates in the next decade.
Expanded Clinical Trials in Low-Income Settings Can Add High Treatment Cost and Limited Access
RVO management is costly, particularly with the need for prolonged anti-VEGF injections, and often a considerable burden for patients, especially in developing and underdeveloped regions. Because of limited reimbursement, no insurance coverage and poor health care infrastructure treatment uptake remains poor. The invasive character and logistical burden of frequent clinical visits renders a significant portion of patients nonadherent to repeated injection schedules.
Advances in Sustained-Release and Gene Therapy-Based Approaches
The market has a huge potential owing to sustained-release formulations and ocular implants, which minimize the need of frequent intravitreal injections. Innovations such as nanotechnology act as biodegradable drug carriers, while gene-editing technologies hold progressive compounds that produce lasting therapies with little intervention. Such advancements could revolutionize the standard of care for RVO and facilitate access by lowering the overall cost of treatment and improving patient compliance.
The global retinal vein occlusion treatment market has been segmented based on type of drug and region, and we observed an uptick in the usage of anti-VEGF and corticosteroid implant drugs from 2020 to 2024. There was did a significant shift to earlier diagnosis supported by advances in optical coherence tomography (OCT) and retinal imaging systems. But treatment adherence was affected by concern with procedure frequency, which has led to the investigation of longer-acting drugs as well as sustained-delivery systems.
From 2025 to 2035, integrated ophthalmic care models are expected to dominate the market, merging AI-based diagnostics with personalized treatment protocols. Novel gene therapy proof-of-concept trials and the commercialization of ocular implants with up to 6 months coverage will continue to redefine treatment protocols. And second, the expansion of biosimilars and the integration of teleophthalmology in the delivery of care will be critical in reducing costs and expanding disease management to areas where patients may otherwise go undiagnosed and untreated.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 |
|---|---|
| Drug Preference | Anti-VEGF dominance |
| Delivery Method | Intravitreal injections |
| Diagnosis | Reliant on manual and semi-automated imaging |
| Market Accessibility | High cost, limited in rural areas |
| Innovation Focus | Drug repurposing and new molecules |
| Market Shift | 2025 to 2035 |
|---|---|
| Drug Preference | Long-acting implants and gene therapy emerging |
| Delivery Method | Sustained-release delivery and ocular implants |
| Diagnosis | AI-assisted OCT and remote monitoring |
| Market Accessibility | Expanded reach via biosimilars and digital health platforms |
| Innovation Focus | Personalized therapies and regenerative medicine in ophthalmology |
An increase in awareness on early-stage diagnosis and access to specialized ophthalmology clinics is contributing towards an increase in treatment uptake. The use of anti-VEGF therapies remains widely used and increasingly preferential towards long-acting injectable formulations.
Furthermore, advancements like AI-assisted retinal imaging and predictive diagnostics are aiding timely intervention and personalized care strategies. Government healthcare reimbursements and innovation from domestic biotech companies are accelerating the development of targeted RVO therapies.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 5.5% |
The UK RVO treatment market is projected to witness a promising CAGR of 5.1% during the next ten years. The country’s National Health Service (NHS) is investing in infrastructure for early detection and increasing access to ophthalmology services, particularly for the elderly.
The rising prevalence of cardiovascular disorders and the emergence of cardiovascular-related, ocular disorders such as central and branch retinal vein occlusion, are further propelling market owing to increased demand for anti-VEGF drugs and corticosteroid implants.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 5.1% |
The European market for retinal vein occlusion therapeutics is anticipated to grow at a CAGR of 5.4% from 2023 to 2035. Germany, France, and Italy are some examples of countries that have high RVO cases due to the context of an ageing population and greater incidence of cardiovascular diseases.
National healthcare systems prioritise ocular health, driving procurement of high-cost biologics and retinal therapeutics. In addition, across the EMA, pan-European clinical trials, and regulatory harmonization, are paving the way for the introduction of biosimilars, alongside innovator therapies. This abundance of ophthalmic clinics, sophisticated imaging systems, and AI-based diagnosis is facilitating patient management in all urban and regional centres.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 5.4% |
The retinal vein occlusion treatment market in Japan is based on the trajectory of growth at which it will register a CAGR of 5.3% during the forecast period of 2025 to 2035. As one of the world’s fastest aging societies, Japan is witnessing a surge in vision-related complications, including RVO.
Vascular endothelial growth factor plays a key role in the development of choroidal neovascularization, leading to various retinal disorders such as wet AMD. Japanese research institutions are also leading the way with gene editing and RNA-based interventions that target reversal of retinal damage. Japan retains its position as a prominent player in the RVO therapeutic development and clinical research landscape with comprehensive public health policies and increasing need for long-acting therapeutics.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 5.3% |
The retinal vein occlusion treatment market in South Korea is anticipated to grow at a CAGR of 5.2% from 2025 to 2035. The rise in age-related vascular disorders and diabetic complications is driving the need for effective interventions in RVO.
Korean biotech companies are introducing biosimilar-based anti-VEGF products to help patients afford and treat expensive long-term treatments. Israel’s robust digital infrastructure and smart hospital programs have also enabled teleophthalmology services to be used for follow-up care and monitoring. In addition, the introduction of AI-based fundus imaging systems within urban and semi-urban regions is taking place in clinics and hospitals for early diagnosis and treatment adaptation as well.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 5.2% |
| By Drug Class | Market Share (2025) |
|---|---|
| Ranibizumab | 39.5% |
Ranibizumab has been well established as the leader RVO agent worldwide for many years since it has demonstrated efficacy to improve visual acuity and reduce macular edema. Ranibizumab (Anti-VEGF) is a VEGF inhibitor directed toward attenuating aberrant neovascularization and vascular permeability in the retina, two key pathologic processes contributing to limiting vision loss from RVO. Due to its acceptable safety profile with consistent visual outcomes across numerous studies, this agent is the most commonly chosen treatment by ophthalmologists for patients with both central and branch retinal vein occlusion.
Healthcare professionals have a preference for Ranibizumab because of the lengthy record of safety and efficacy and availability in the treatment guidelines published by the prominent ophthalmic associations. Administering the drug intravitreally provides localized effects and reduced off-target effects. In particular, the pharmaceutical co. actively promotes Ranibizumab with patient assistance programs and education initiatives for timely diagnosis and treatment compliance.
In addition, it has received approval in North America, Europe and Asia-Pacific, giving it traction within the global market. Manufacturers are excited to continue innovating with extended-release formulations and biosimilar development to avoid the high cost burden of chronic treatment cycles. In the future, development of awareness and accessibility of retinal care may enable the senior populace to receive appropriate treatment in a timely manner. However, Ranibizumab continues to remain the cornerstone of therapeutic contention in the RVO field.
| By Type | Market Share (2025) |
|---|---|
| Central Retinal Vein Occlusion (CRVO) | 56.8% |
The largest share of the market is for central retinal vein occlusion (CRVO) in association with severe clinical presentation and the requirement for aggressive therapeutic intervention. CRVO is the obstruction of the main vein responsible for draining blood from the retina, resulting in acute vision loss, hemorrhages, and macular edema. Higher demand for the treatment of CRVO cases is found in ophthalmic clinics and hospitals, particularly among patients older than 60 years with comorbidities such as hypertension, diabetes, and glaucoma.
Treatment of CRVO is usually done with regular intravitreal injections, thereby leaving these patients dependent on regular clinical care and drug management. OCT imaging and fluorescein angiography are used to monitor CRVO patients, causing healthcare providers to adjust dosing schedules and evaluate retinal recovery. The complexes and progressive aspect of CRVO also supports early intervention, usually in the form of anti-VEGF agents such as Ranibizumab, or corticosteroids like Dexamethasone.
With an aged population and increasing prevalence of chronic diseases in contemporary countries, we estimate that cases of the disease will increase in numbers especially in urban and high-income areas. The pharmaceutical players meet this demand through endeavors in clinical research, long-acting drug delivery, and awareness campaigns among others. The disparity in clinical focus and treatment intensity results in CRVO being the more lucrative and dominant segment of the RVO treatment market.
Factors contributing to the growth of rvo treatment market include increasing retinal vascular diseases, more availability of therapeutic options and growing awareness regarding eye health. The companies are actively engaged in research and development, collaborations and enhanced pipeline to strengthen their position in the market ranging from innovations in anti-vascular endothelial growth factor (Anti-VEGF) therapies, corticosteroid drugs to biosimilars.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Regeneron Pharmaceuticals Inc. | 18 - 20% |
| Genentech Inc. (F. Hoffmann-La Roche Ltd.) | 16 - 18% |
| Bayer AG | 14 - 16% |
| Novartis AG | 12 - 14% |
| Other Companies (combined) | 32 - 40% |
| Company Name | Key Offerings/Activities |
|---|---|
| Regeneron Pharmaceuticals Inc. | In 2024, expanded the use of EYLEA® (aflibercept) for treating macular edema following RVO, reinforcing its position in the anti-VEGF therapy segment. |
| Genentech Inc. (F. Hoffmann-La Roche Ltd.) | In 2025, reintroduced Susvimo® (ranibizumab injection) 100 mg/mL in the USA market, offering a sustained delivery treatment option for RVO patients. |
| Bayer AG | In 2024, collaborated with Regeneron to co-promote EYLEA® globally, enhancing its reach in the RVO treatment market. |
| Novartis AG | In 2025, advanced the development of Beovu® (brolucizumab) for RVO treatment, aiming to provide longer-lasting therapeutic effects. |
Key Company Insights
Regeneron Pharmaceuticals Inc. (18-20%)
A well-adopted therapy for branch and central RVO, EYLEA® has been shown to decrease macular edema and improve visual acuity.
Genentech Inc. (F. Hoffmann-La Roche Ltd.) (16-18%)
Genentech explores reopening delivery systems, Susvimo® is a refillable ocular implant for the continuous delivery of ranibizumab for RVO treatment.
Bayer AG (14-16%)
Bayer is the co-promotion partner of Regeneron outside the USA for EYLEA® and has significantly invested in increasing patient access to this effective RVO therapy worldwide.
Novartis AG (12-14%)
Beovu® (brolucizumab), being developed by Novartis for RVO, is supported by data in its extended dosing intervals to alleviate treatment burden
Other Key Players (32-40% Combined)
Several other companies contribute significantly to the RVO treatment market through specialized offerings:
The overall market size for the retinal vein occlusion treatment market was USD 2,579.4 million in 2025.
The retinal vein occlusion treatment market is expected to reach USD 4,323.1 million in 2035.
The demand is driven by the increasing prevalence of diabetes and hypertension, advancements in treatment modalities such as anti-VEGF drugs and laser therapies.
The top 5 countries driving market growth are the USA, UK, Europe, Japan, and South Korea.
The central retinal vein occlusion segment is expected to command a significant share over the assessment period.
Retinal Vein Occlusion Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
